- Report
- December 2023
- 132 Pages
Global
From €912EUR$950USD£786GBP
- Report
- April 2023
- 260 Pages
Global
From €3429EUR$3,570USD£2,952GBP
- Report
- November 2023
- 160 Pages
Global
From €2880EUR$2,999USD£2,480GBP
- Report
- March 2022
- 132 Pages
Global
From €4322EUR$4,500USD£3,721GBP
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons in the brain and spinal cord. As a result, patients experience muscle weakness, paralysis, and eventually death. The ALS drug market is a subset of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. The ALS drug market is relatively small compared to other CNS drug markets, but it is growing due to increased awareness and research into the disease.
The ALS drug market is composed of both generic and branded drugs. Generic drugs are typically used to treat the symptoms of ALS, while branded drugs are used to slow the progression of the disease. Currently, there are several companies that are actively researching and developing new treatments for ALS, including Biogen, Novartis, and Sanofi. Additionally, there are several companies that are focused on providing generic drugs to treat the symptoms of ALS, such as Mylan and Teva Pharmaceuticals. Show Less Read more